Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accounts Payables: 2023-2025

Historic Accounts Payables for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $6.8 million.

  • Inhibrx Biosciences' Accounts Payables fell 45.25% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 45.25%. This contributed to the annual value of $9.2 million for FY2024, which is 15.60% down from last year.
  • Inhibrx Biosciences' Accounts Payables amounted to $6.8 million in Q3 2025, which was down 18.32% from $8.3 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Accounts Payables high stood at $13.0 million for Q2 2024, and its period low was $6.8 million during Q3 2025.
  • Moreover, its 3-year median value for Accounts Payables was $9.2 million (2024), whereas its average is $9.9 million.
  • Data for Inhibrx Biosciences' Accounts Payables shows a maximum YoY crashed of 45.25% (in 2025) over the last 5 years.
  • Inhibrx Biosciences' Accounts Payables (Quarterly) stood at $11.0 million in 2023, then dropped by 15.60% to $9.2 million in 2024, then slumped by 45.25% to $6.8 million in 2025.
  • Its Accounts Payables stands at $6.8 million for Q3 2025, versus $8.3 million for Q2 2025 and $8.9 million for Q1 2025.